In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.
Andrew Davies, PhD
Advertisement
Articles by Andrew Davies, PhD
Advertisement
Latest Updated Articles
Longer Term Data Confirm Subcutaneous Rituximab Efficacy in Follicular LymphomaPublished: December 8th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
4
Leveraging Novel Software to Further Improve Personalized Cancer Care
5
